Jane Street Group LLC Sells 60,340 Shares of Standard BioTools Inc. (NASDAQ:LAB)

Jane Street Group LLC decreased its holdings in Standard BioTools Inc. (NASDAQ:LAB) by 24.9% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 181,814 shares of the company’s stock after selling 60,340 shares during the period. Jane Street Group LLC’s holdings in Standard BioTools were worth $351,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of LAB. Bank of New York Mellon Corp increased its position in shares of Standard BioTools by 1,019.8% during the second quarter. Bank of New York Mellon Corp now owns 980,983 shares of the company’s stock worth $1,736,000 after purchasing an additional 893,383 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Standard BioTools by 184.5% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 50,330 shares of the company’s stock valued at $89,000 after buying an additional 32,640 shares during the last quarter. Principal Financial Group Inc. purchased a new stake in shares of Standard BioTools during the second quarter valued at $57,000. Rhumbline Advisers boosted its holdings in Standard BioTools by 3,691.1% in the second quarter. Rhumbline Advisers now owns 407,467 shares of the company’s stock valued at $721,000 after purchasing an additional 396,719 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its holdings in Standard BioTools by 27.3% in the second quarter. Victory Capital Management Inc. now owns 46,967 shares of the company’s stock valued at $83,000 after purchasing an additional 10,067 shares during the last quarter. Institutional investors own 53.74% of the company’s stock.

Standard BioTools Stock Down 0.6 %

LAB stock opened at $1.75 on Thursday. Standard BioTools Inc. has a 52-week low of $1.21 and a 52-week high of $3.04. The company’s 50-day simple moving average is $1.87 and its 200-day simple moving average is $1.90. The firm has a market cap of $651.46 million, a P/E ratio of -2.46 and a beta of 1.61.

Analyst Upgrades and Downgrades

Separately, TD Cowen lowered their price target on shares of Standard BioTools from $2.75 to $2.50 and set a “buy” rating on the stock in a report on Thursday, October 31st.

Standard BioTools Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.